TEV-56278

· Teva Branded Pharmaceutical Products R&D LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TEV-56278, covering 2026-04-21 to 2026-04-21. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors [Phase 1]

See pricing